Which biomarker tests (ER/PR, HER2) are recommended for breast cancer

Biomarker Testing for Metastatic Breast Cancer

Great question! Understanding which tests your care team recommends is an important part of your treatment planning. Let me explain the key biomarkers and why they matter.

The Three Main Biomarker Tests

According to the NCCN Guidelines for Patients: Metastatic Breast Cancer, testing should include:

1. Hormone Receptor Status (ER/PR)

What it is: Your care team tests for two hormone receptors—estrogen receptor (ER) and progesterone receptor (PR). These are proteins found inside or on breast cancer cells that respond to hormones in your body.

Why it matters:

• When hormones attach to these receptors, they can signal cancer cells to grow
• If your cancer is hormone receptor-positive (HR+), doctors can use endocrine therapy (hormone-blocking treatments) to stop this growth signal
• Most breast cancers are HR+, which means treatment options may include hormone-blocking medications

How it's tested: A biopsy sample is examined using immunohistochemistry (IHC), a special staining process that allows pathologists to see these receptors under a microscope.

2. HER2 Status

What it is: HER2 (human epidermal growth factor receptor 2) is a protein that can appear on the surface of breast cancer cells. Some cancers have extra copies of the HER2 gene, making them HER2-positive.

Why it matters:

• HER2-positive cancers tend to grow faster
• If your cancer is HER2-positive, doctors have specific targeted therapies designed to block HER2 signals
• This information directly shapes your treatment options

How it's tested: Similar to ER/PR testing, HER2 is identified through immunohistochemistry or other specialized methods like FISH (fluorescence in situ hybridization).

3. Additional Biomarker Testing

Beyond ER/PR and HER2, the NCCN Guidelines note that your care team may test for other mutations depending on your specific situation:

• Tumor mutation testing can identify mutations like PIK3CA, AKT1, PTEN, ESR1, NTRK, and RET—some of which can be targeted with specific therapies
• PD-L1 testing (immune checkpoint protein) may be recommended, especially for triple-negative breast cancers
• BRCA1/2 genetic testing is recommended for all patients with metastatic breast cancer (unless already done recently)

Important Points About Testing

According to NCCN Guidelines:

• Hormone receptor testing should be done on any new tumors to get the most current information
• Testing takes time—it might take days or weeks for all results to come back
• Your biopsy sample will be analyzed by a pathologist who measures how many cells have these receptors

Questions to Ask Your Care Team

1. Which biomarker tests have been done on my cancer, and what were the results?
2. What do my specific ER/PR and HER2 results mean for my treatment options?
3. Are there any other biomarker tests you recommend based on my cancer type?
4. How do these test results affect which treatments might work best for me?
5. Will you retest if my cancer changes or if I get a new biopsy?

Why This Matters

These biomarker tests are the foundation of personalized cancer treatment. They help your oncology team understand what kind of breast cancer you have and which treatments are most likely to work effectively for your specific situation. That's why getting clear, complete test results is so important.

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.